Navigation Links
RNA interference therapy heals growth deficiency disorder in a live animal
Date:12/18/2007

ay to correct this disorder.

In the last 15 years, scientists have realized that short pieces of double-stranded RNA, called silencing-RNA, use a pathway that is normally used by cells to regulate genes. This has created an opportunity for developing highly targeted therapies for a number of genetic diseases including macular degeneration in the eye and to block viruses such as herpes and RSV respiratory viruses. To the best of our knowledge, this is the first time it has been used to correct a dominant negative disorder in a living animal, says Patton.

The researchers realized that the messenger-RNA that produced the defective hormone had a unique signature created by skipping the third exon. This allowed the Patton lab to create a specific silencing-RNA, designed to bind uniquely with the defective messenger-RNA.

You might call this the if you dont like the message, kill the messenger approach, Phillips quips.

Having created the special silencing-RNA, the next problem was how to deliver it to the pituitary gland which, in the case of the mouse, is the size of a grain of uncooked rice and is located at the base of the brain. As a proof of concept, the researchers decided to create a second strain of mouse which carried the special silencing-RNA and mate them with the growth deficiency strain. Their offspring should have both the genetic defect that produces the defective growth hormone and the silencing-RNA that should inhibit its production, allowing the mouse growth hormone to act.

The experiment was successful. The offspring grew normally and showed no defects in their pituitaries.

Now the researchers are investigating ways to deliver their silencing-RNA to the pituitary gland that would be suitable for treating humans. The cells that produce growth hormone have special receptors that signal the cells to release their stocks of growth hormone. If they can figure out a way to attach the silencing-RNAs to a compound that binds to this rece
'/>"/>

Contact: David F. Salisbury
david.salisbury@vanderbilt.edu
615-343-6803
Vanderbilt University  
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. A new radiation therapy treatment developed for head and neck cancer patients
2. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. MIT works toward safer gene therapy
5. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
6. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
7. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
8. Safe and effective therapy discovered for patients with protein-losing enteropathy
9. Ireland Cancer Center researchers advance stem cell gene therapy
10. Dolphin therapy a dangerous fad, Emory researchers warn
11. Cancer and arthritis therapy may be promising treatment for diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
RNA interference therapy heals growth deficiency disorder in a live animal
(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3First Atlanta Science Festival set for 2014 2
... may emerge from a laboratory model that has just been ... human immune stem cells from umbilical cord blood into mice ... live alongside the mouse,s own immune system. Although mice ... causes typhoid fever, the bacteria are able to reproduce in ...
... Md. (September 22, 2010) The National Science Foundation ... Science Chesapeake Biological Laboratory $1.7 million to repair and ... Since 1936, the pier has played an instrumental role ... on climate change, fisheries management and the health of ...
... The antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, ... long-sought new treatment for a parasitic disease that affects ... became the guiding light for future development of drugs ... Medicinal Chemistry . In the study, Rima McLeod ...
Cached Biology News:Humanized mice may provide clues to better prevent and treat typhoid fever 2Humanized mice may provide clues to better prevent and treat typhoid fever 3UMCES Chesapeake Biological Laboratory to rebuild historic research pier 2
(Date:5/19/2013)... 2013 The JM Internet Group (web: ... has proudly announced that the company's YouTube channel on ... 175,000 views on YouTube. The company uses YouTube as ... tips and training for small businesses with much success. ... YouTube tips helpful for their SEO strategies", explained Jason ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Dr. Sparano ... and Women’s Health at the Albert Einstein College of ... at the Montefiore Medical Center. He is also ... Center and leads the Einstein Breast Cancer Working Group, ... translational breast cancer research. He also serves as Vice ...
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... 17, 2013 - Elsevier, a world-leading provider of scientific, ... the publication of a recent study in ... blastocysts showing that those with an abnormal chromosomal composition ... have developed to blastocysts, thereby classifying the risk of ... the same group has undertaken a retrospective study, using ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3
... and the public agree that the promise of nanotechnology is ... be governed accordingly. , The new technology, which is ... to computers, is seen differently among scientists than the general ... areas. But in broad categories of risk versus reward both ...
... N.Y., Feb. 15 EUSA Pharma (Oxford, UK), ... licensed OP-R003,a human anti-interleukin-6 antibody discovered by Vaccinex, ... product license, GSK will pay an up-front,license fee, ... the exclusive world-wide rights to develop and commercialize,OP-R003 ...
... Data presented at the 2008 Genitourinary Cancers ... OncoGenex Technologies Inc. announced,today that the Company,s ... as custirsen, was well-tolerated in combination with ... in patients with,hormone refractory prostate cancer. Additionally, ...
Cached Biology Technology:Nanotech's health, environmental impacts worry scientists and the public 2Nanotech's health, environmental impacts worry scientists and the public 3Vaccinex Antibody Licensed to GlaxoSmithKline 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 3OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 4
Complete cell culture media with cytokines...
Request Info...
Contains 0.2 g/L EDTA4Na in phosphate-buffered saline....
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
Biology Products: